In another preliminary study on metastatic renal cell carcinoma (96), 18 patients with clear cell carcinoma and 11 patients with non-clear cell carcinoma underwent treatment with anti-CTLA-4 (Tremelimumab) monotherapy (n=14) or a combination of cryoablation and anti-CTLA-4 (n=15). The gene discussed is CTLA4; the disease is clear cell adenocarcinoma.